To include your compound in the COVID-19 Resource Center, submit it here.

Lilly's lasmiditan passes second Phase III test

Eli Lilly and Co. (NYSE:LLY) said lasmiditan (oral COL-144) met the primary endpoint in a second Phase III trial to

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE